Key Takeaways CHMP backed Nucala as an add-on therapy for COPD, with a European decision expected in early 2026.A monthly injectable Nucala targets IL-5 to help uncontrolled COPD patients reduce hospital visits.Depemokimab won CHMP support after studies showed twice-yearly efficacy in asthma and CRSwNP.GSK plc (GSK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending the approval of Nucala as an add-on main ...